Thermoplastic Polymer Melt Crystallization for Microcrystal Uniformity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing dosage forms of sparingly-soluble active substances face challenges such as long grinding times, abrasive wear, contamination, and inadequate storage stability due to low glass transition temperatures of polyethylene glycols, which also pose compatibility issues with oxidation-sensitive substances.
Innovation Solution
A method involving the dissolution of an active substance in a thermoplastic polymer melt with a glass transition temperature of at least 40°C, followed by controlled crystallization and cooling, embedding the microcrystals in a polymer matrix to stabilize them and enhance bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If controlled crystallization from polymer melt is used, then manufacturing precision of microcrystal size is improved, but device complexity increases
Solution Approach 1:
The invention controls microcrystal size and uniformity by precisely managing temperature parameters during the crystallization process. The polymer melt is cooled at controlled rates from the melting point through the crystallization temperature range, and the process is terminated at a specific temperature. This systematic parameter control enables reproducible production of microcrystals with consistent size distribution (500 nm to 100 μm) without requiring complex equipment modifications.
2Ease of manufacture
If polyethylene glycol is used as the polymer matrix, then ease of manufacture is improved, but reliability deteriorates due to low glass transition temperature and peroxide formation
Solution Approach 1:
The invention changes the key parameter of glass transition temperature by selecting polymers with Tg ≥ 40°C, specifically excluding polyethylene glycols which have Tg < 0°C. This parameter change eliminates the cold flow and storage stability problems associated with low Tg polymers while maintaining the ease of manufacture benefits through the use of thermoplastic polymers that can be processed by melting and cooling.
Solution Approach 2:
The invention turns the potential harm of polymer selection into a benefit by choosing polymers whose properties (higher Tg, peroxide resistance) directly address the reliability issues. The exclusion of polyethylene glycols based on their harmful characteristics (peroxide formation, low Tg) leads to the selection of polymers that inherently provide better storage stability and compatibility with oxidation-sensitive active substances.
3Reliability
If active substance is comminuted to very small particles, then bioavailability is improved, but loss of time increases due to very long grinding times
Solution Approach 1:
The invention replaces the mechanical grinding system with a thermal-crystallization system. Instead of using mechanical force to comminute particles over long periods, the process uses temperature control to induce crystallization of the active substance from the polymer melt. This substitution of the fundamental mechanism (mechanical → thermal) achieves fine particle size (500 nm to 100 μm) in a fraction of the time required for conventional grinding.
Solution Approach 2:
The invention exploits the phase transition of the active substance from dissolved state to crystalline state during controlled cooling of the polymer melt. As the temperature decreases through the crystallization range, the active substance precipitates as fine microcrystals embedded in the polymer matrix. This phase transition mechanism naturally produces small, uniform particles without the time-consuming mechanical comminution required by conventional methods.
4Reliability
If active substance is comminuted to very small particles, then bioavailability is improved, but object-generated harmful factors increase due to abrasive wear and contamination
Solution Approach 1:
The invention replaces the mechanical grinding system that causes abrasive wear and contamination with a thermal-crystallization system. The active substance is processed in a molten state and then crystallized in situ within the polymer matrix, eliminating contact with grinding media and the associated wear and contamination problems. This results in pure active substance particles without mechanical degradation or foreign particle contamination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the reproducible production of small, uniform microcrystals of active substances, improving bioavailability by preventing agglomeration and enhancing solubilization, while maintaining stability and compatibility with oxidation-sensitive compounds.
Implementation Method 1
an active substance is dissolved homogeneously in the melt of a thermoplastic polymer
Implementation Method 2
crystallization of the active substance is initiated in the mass obtained; the mass is cooled
Data Source
AI summary
A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.